Peregrine Asset Advisers’s NovoCure NVCR Stock Holding History

Peregrine Asset Advisers’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,072	Closed	-$831K	–	137
2021 Q4	$831K	Sell	11,072 -55	-0.5%	-$5.52K	0.34%	61
2021 Q3	$1.29M	Buy	11,127 +1,568	+16%	+$237K	0.66%	44
2021 Q2	$2.12M	Buy	+9,559	New	+$1.86M	0.97%	40
2021 Q1	–	Sell	-1,162	Closed	-$201K	–	139
2020 Q4	$201K	Buy	+1,162	New	+$159K	0.09%	126

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Peregrine Asset Advisers's NVCR Position: Q1 2022 in Review

Peregrine Asset Advisers sold out of NovoCure (NVCR) in Q1 2022, closing a stake of 11,072 shares — an estimated $831K sold.

Peregrine Asset Advisers first reported a position in NVCR in Q4 2020 and held it in 4 quarters. The position peaked at $2.12M in Q2 2021. 308 funds tracked by Wall St. Rank hold NVCR as of Q1 2022.

Peregrine Asset Advisers reported no remaining NovoCure position as of Q1 2022 after selling out during the quarter.
Peregrine Asset Advisers sold 11,072 NovoCure shares in Q1 2022, an estimated $831K.
Peregrine Asset Advisers first reported a position in NovoCure in Q4 2020 and held it in 4 quarters.
Peregrine Asset Advisers's NovoCure position peaked at $2.12M in Q2 2021.
308 funds tracked by Wall St. Rank held NovoCure as of Q1 2022.

Based on Peregrine Asset Advisers's 13F filing for Q1 2022, filed 5 May 2022.